Hematology

Latest News

In a 100-patient clinical practice scenario, cost savings with zanubrutinib vs ibrutinib would amount to $4.7 million. | Image credit: sovova - stock.adobe.com
Zanubrutinib May Lead to Cost Savings vs Ibrutinib in R/R CLL

April 15th 2025

Progression-free survival improvement and drug costs make zanubrutinib a more cost-effective option in relapsed or refractory chronic lymphocytic leukemia (CLL), new research suggests.

Orca-T shows promise to reduce rehospitalization and improve outcomes in MDS and acute leukemias.| Image credit: Eleni - stock.adobe.com
Reduced Rehospitalizations and Potential Cost Savings With Orca-T for Acute Leukemia, MDS

April 11th 2025

The researchers examined outcomes in a series of patients with RT who were treated with liso-cel, including patients who were also taking ibrutinib. | Image credit: AIGen - stock.adobe.com
Ibrutinib May Boost Efficacy of Liso-Cel in CLL With Richter Transformation

April 10th 2025

Recent trials have explored potential strategies for using immunotherapy in chronic lymphocytic leukemia. | Image credit: Spectral-Design - stock.adobe.com
Immune Microenvironment a Key Target in CLL

April 8th 2025

Health equity concept | image credit: VectorMine - stock.adobe.com
Advancing MM Care Through Innovation and Equity: Ajai Chari, MD

April 7th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

MRD status cannot be detected with a microscope and is achieved through bone marrow analysis | image credit: Arthur Constantine - stock.adobe.com
January 13th 2025

MRD Negativity: A "Robust" Predictor of Survival Outcomes in MM

Kyle Munz
This meta-analysis sheds more light on the beneficial impact of multiple melanoma (MM) treatments and the predictive value of minimal residual disease (MRD) status for patient prognoses.
Donating blood can save more than 1 life | image credit: Creative Cat Studio - stock.adobe.com
January 10th 2025

5 Things to Know About Donating Blood

Kyle Munz
Here are 5 things individuals should know about the powerful impact of blood donation and the benefits becoming a donor can have for patients in need.
mRNA vaccines can boost T cell responses | image credit: myskin - stock.adobe.com
January 9th 2025

Study Advocates Immunological Value of COVID-19 Vaccination in MM

Kyle Munz
Patients with multiple myeloma (MM) can experience diminished immune responses during prolonged treatment; however, mRNA vaccines could bolster immunity in this vulnerable population.
MRD ahead of allo-HSCT showed prognostic value in patients with AML and MDS. | Image credit: keetazalay - stock.adobe.com
January 6th 2025

MRD Status Prior to Allo-HSCT Shows Strong Prognostic Value in AML, MDS

Kimberly Rath, PharmD
A study demonstrated that pre-transplant measurable residual disease (MRD) status is a strong prognostic factor for overall survival, disease-free survival, and relapse risk in patients with AML and MDS undergoing allogeneic stem cell transplantation.
Among 55 evaluable samples analyzed, QPOP achieved an 87.3% success rate in generating individualized drug sensitivity reports. | Image credit: Eleni - stock.adobe.com
January 6th 2025

Functional Precision Medicine Tool Predicts Treatment Response in AML

Kimberly Rath, PharmD
A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug combination sensitivities, paving the way for improved treatment strategies and outcomes in acute myeloid leukemia (AML).
Don M. Benson, MD, PhD, James Cancer Hospital
January 2nd 2025

Honoring Patient Wishes in Myeloma Treatment Journeys

Maggie L. Shaw
In our ongoing conversation with James Cancer Hospital’s Don M. Benson, MD, PhD, he explains his philosophy of always striving to deliver personalized patient care.
ASH thumbnail
December 29th 2024

ICYMI: Highlights From ASH 2024

Maggie L. Shaw
The 66th American Society of Hematology (ASH) Annual Meeting & Exposition took place December 7-10, 2024, in San Diego, California; the 2025 meeting is currently scheduled to take place in Orlando, Florida, December 6-9.
MM Top 5 Thumbnail
December 24th 2024

Top 5 Multiple Myeloma Content of 2024

Maggie L. Shaw
Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow was showcased.
A subpopulation of patients with CLL/SLL and secondary immunodeficiency disease carry increased infection risks | image credit: sdecoret - stock.adobe.com
December 19th 2024

Infection Rate More Than Doubles in CLL/SLL Accompanied by Secondary Immunodeficiency Disease

Karen Jacobson-Sive
Secondary immunodeficiency disease (SID) status was associated with significantly higher risk for severe bacterial infections in adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
Older patients with AML or MDS do not always receive the same care recommendations, a study found | image credit: Orawan - stock.adobe.com
December 19th 2024

Canadian Study Highlights Care Variability for Older Patients With MDS/AML

Kimberly Rath, PharmD
A national survey of Canadian hematologists reveals gaps and variability in supportive care strategies for older adults with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), emphasizing the need for evidence-based guidelines.
MDS graphic | Image Credit: © Sviatlana-stock.adobe.com
December 18th 2024

Luspatercept Promising Against Anemia in MDS

Kimberly Rath, PharmD
Findings from a phase 2 trial show that luspatercept effectively improves anemia in patients with lower-risk myelodysplastic syndromes (MDS), enabling them to delay or prevent transfusion dependence while maintaining a favorable safety profile.
ICYMI: Highlights From IMS 2024
December 17th 2024

ICYMI: Highlights From IMS 2024

Maggie L. Shaw
The expert knowledge presented at this year’s International Myeloma Society (IMS) annual meeting focused on minimal residual disease testing and status, defining and treating high-risk disease, CEPHEUS trial findings, and an investigational off-the-shelf chimeric antigen receptor T-cell therapy.
MDS | Image Credit: © ibreakstock-stock.adobe.com
December 11th 2024

Molecular Lesions in Low-Risk Myelodysplastic Neoplasms Disrupt Prognostic Model for Leukemia

Karen Jacobson-Sive
Conventional parameters for risk stratification prognosis for patients with low-risk myelodysplastic neoplasms, especially bone marrow blast percentage, drop their clinical significance once molecular lesions are included in prognostic scores.
CLL cells magnified/stained | image credit: jarun011 - stock.adobe.com
December 10th 2024

6-Year Data Support Fixed-Duration Ven-Obi for Untreated CLL

Jared Kaltwasser
Long-term data support the safety and efficacy of venetoclax (Venclexta) and obinutuzumab (Gazyva) in chronic lymphocytic leukemia (CLL), though questions remain about which patients would benefit most from the regimen.
Matias Sanchez, MD
December 2nd 2024

Balancing Cutting-Edge Therapies With Cost in Multiple Myeloma Treatment

Skylar Jeremias
Matias Sanchez, MD, assistant professor in the Department of Medicine at the University of Illinois Chicago, discussed recent advancements in multiple myeloma treatment, including the potential of cell therapies and bispecific antibodies.
New evidence suggest a slight connection between receiving a tattoo and elevated cancer risks | image credit: xartproduction - stock.adobe.com
November 29th 2024

Tattoos May Be Associated With Increased Risk of Rare NHLs

AJMC Contributor
Despite found associations, due to small sample sizes the researchers suggest readers interpret their findings with caution.
Matias Sanchez, MD
November 29th 2024

Transforming Multiple Myeloma Care With Education and Advanced Therapies

Skylar Jeremias
Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver involvement in managing complex therapies and advises oncologists to confidently integrate advanced treatments.
FDA Approval | image credit: gomixer - stock.adobe.com
November 26th 2024

FDA Approves Imatinib Oral Solution for Treatment of Various Cancers

Kyle Munz
The FDA approval marks the first oral solution indicated for patients with different forms of leukemia.
Guidelines | Image Credit: © momius-stock.adobe.com
November 26th 2024

NCCN Guidelines Prioritize Quad Therapy in Multiple Myeloma

Maggie L. Shaw
In the most recent update to the National Comprehensive Cancer Network (NCCN) guidelines for treating patients who have multiple myeloma, a quadruplet regimen became the preferred first-line treatment option for transplant-eligible and -ineligible patients.
Clinical trial results-Egor-stock.adobe.com.jpeg
November 26th 2024

Progression-Free Survival in Relapsed Multiple Myeloma Extended With Ixazomib, Data Show

Giuliana Grossi
Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies in improving outcomes, particularly in regions with limited access to chimeric antigen receptor T cells and bispecific antibodies.
Big Data | Image Credit: © Friends Stock-stock.adobe.com
November 26th 2024

Real-World Data Confirm Ibrutinib's Role in Relapsed CLL

Gayle Turim Dickstein
This multiyear follow-up of more than 3300 patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) who received ibrutinib—the longest study of its kind—confirms the agent’s efficacy as a salvage treatment but reveals new information about its impact in different subpopulations with varying clinical characteristics.
Don M. Benson, MD, PhD, James Cancer Hospital
November 22nd 2024

Balancing Life and Myeloma: A Patient-Centered Approach

Maggie L. Shaw
In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Elevating Value in Cancer Care With Innovations, Accessibility, Equity
November 21st 2024

Elevating Value in Cancer Care With Innovations, Accessibility, Equity

Cameron Santoro
Coverage from the IVBM Regional event in Denver, Colorado.
AML cells concept | image credit: sovova - stock.adobe.com
November 21st 2024

Study Reveals Leukemia Transplant Successes and Persistent Relapse Risks

Kimberly Rath, PharmD
Long-term survival rates for patients with leukemia after hematopoietic cell transplantation (HCT) are encouraging but personalized transplant strategies remain important to improve outcomes.
Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com
November 19th 2024

OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

Jordyn Sava
The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Don M. Benson, MD, PhD, James Cancer Hospital
November 15th 2024

Elevating Myeloma Care Amidst Complex Treatment Choices

Maggie L. Shaw
Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.
Genes - CrazyJuke - stock.adobe.com
November 15th 2024

NUP98 Rearrangements Linked to Poor Outcomes in AML

Kimberly Rath, PharmD
Findings of a recent study indicate that NUP98 rearrangements can significantly impact outcomes in patients with acute myeloid leukemia (AML).
Tacrolimus | Image Credit: © MQ-Illustrations - stock.adobe.com
November 7th 2024

Tacrolimus Linked to Lower Acute GVHD Risk

Kimberly Rath, PharmD
Posttransplantation treatment with either tacrolimus or cyclosporine A results in favorable outcomes, but tacrolimus may be better at preventing severe graft-versus-host disease (GVHD), according to new study findings.
Blood cells from blood marrow biopsy | image credit: Катерина Євтехова - stock.adobe.com
November 2nd 2024

Patients With MDS Disagree With Physicians About Symptom Frequency

Jared Kaltwasser
Physicians also differed from caregivers when asked how many hours of caregiving patients required each week.
New therapies for AML and other blood cancers may be informed by the overexpression of 3 proteins | image credit: jovannig - stock.adobe.com
November 2nd 2024

New Work Highlights Proteins as Potential Novel AML Therapeutic Targets

Gayle Turim Dickstein
Three proteins—THRAP3, STMN1, and GNA13—are overrepresented in blood cancers like acute myeloid leukemia (AML) and could prove to be novel targets for future therapies.
<12345678
...
26>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo